Instituto de Investigación Sanitaria Bioaraba-ko ikertzaileekin lankidetzan egindako argitalpenak (12)

2024

  1. Acetazolamide-induced pulmonary oedema: A disproportionality analysis from the EudraVigilance database

    British Journal of Clinical Pharmacology, Vol. 90, Núm. 7, pp. 1751-1755

  2. Elimination of hepatitis C virus in a prison: An 18-year experience

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 42, Núm. 5, pp. 236-241

  3. Incorporating the One Health philosophy into pharmacovigilanc: Pharmacovigilance

    British Journal of Clinical Pharmacology

  4. Intranasal esketamine and manic symptoms: A disproportionality analysis in EudraVigilance

    European Neuropsychopharmacology

  5. [Translated article] Pharmaceuticals in the environment: A hospital pharmacy perspective

    Farmacia Hospitalaria, Vol. 48, pp. TS13-TS20

2023

  1. Analysis of heat stroke and heat exhaustion cases in EudraVigilance pharmacovigilance database

    European Journal of Clinical Pharmacology, Vol. 79, Núm. 5, pp. 679-685

2022

  1. Drugs used during the COVID-19 first wave in Vitoria-Gasteiz (Spain) and their presence in the environment

    Science of the Total Environment, Vol. 820

  2. Hazardous drugs (NIOSH's list-group 1) in healthcare settings: Also a hazard for the environment?

    Science of the Total Environment, Vol. 817

  3. Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study

    Journal of Intensive Care, Vol. 10, Núm. 1

  4. Subacute thyroiditis and COVID-19 vaccines: a case/non-case study

    Endocrine, Vol. 77, Núm. 3, pp. 480-485

2021

  1. Pharmacotherapeutic management of Parkinson's disease inpatients: How about asking hospital pharmacists?

    European Journal of Hospital Pharmacy, Vol. 28, Núm. e1, pp. E140-E145

  2. Population pharmacokinetics of levetiracetam and dosing evaluation in critically ill patients with normal or augmented renal function

    Pharmaceutics, Vol. 13, Núm. 10